Hubei Guangji Pharmaceutical Co Ltd (000952) — Strategic Asset Allocation Index
Hubei Guangji Pharmaceutical Co Ltd (000952) has a Strategic Asset Allocation Index of 84.2% as of September 2023. Strategic assets (PP&E of CN¥1.25 Billion plus long-term investments of CN¥-) total CN¥1.25 Billion, measured against net assets of CN¥1.48 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Hubei Guangji Pharmaceutical Co Ltd Strategic Asset Allocation Index (2000–2022)
This chart shows how Hubei Guangji Pharmaceutical Co Ltd's Strategic Asset Allocation Index has evolved across 23 annual periods from 2000 to 2022. As of September 2023, the index stands at 84.2%, representing strategic assets of CN¥1.25 Billion against net assets of CN¥1.48 Billion CNY. Explore 000952 cash generation efficiency to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Hubei Guangji Pharmaceutical Co Ltd (2000–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Hubei Guangji Pharmaceutical Co Ltd from 2000 to 2022, covering 23 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Hubei Guangji Pharmaceutical Co Ltd stock valuation.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 80.4% | CN¥1.20 Billion | CN¥1.20 Billion | CN¥- | CN¥1.49 Billion | ▲ +6.7 pp |
| 2021 | 73.7% | CN¥1.07 Billion | CN¥1.07 Billion | CN¥- | CN¥1.45 Billion | ▼ -2.6 pp |
| 2020 | 76.3% | CN¥1.04 Billion | CN¥1.04 Billion | CN¥- | CN¥1.37 Billion | ▼ -23.6 pp |
| 2019 | 99.9% | CN¥963.40 Million | CN¥963.40 Million | CN¥- | CN¥964.30 Million | ▼ -12.6 pp |
| 2018 | 112.5% | CN¥991.11 Million | CN¥959.49 Million | CN¥31.62 Million | CN¥880.96 Million | ▼ -18.6 pp |
| 2017 | 131.1% | CN¥1.00 Billion | CN¥969.34 Million | CN¥34.03 Million | CN¥765.24 Million | ▼ -22.1 pp |
| 2016 | 153.2% | CN¥1.01 Billion | CN¥974.43 Million | CN¥35.48 Million | CN¥659.18 Million | ▼ -37.8 pp |
| 2015 | 191.0% | CN¥981.49 Million | CN¥942.54 Million | CN¥38.95 Million | CN¥513.86 Million | ▲ +21.9 pp |
| 2014 | 169.1% | CN¥854.65 Million | CN¥854.65 Million | CN¥- | CN¥505.45 Million | ▲ +28.1 pp |
| 2013 | 141.0% | CN¥1.04 Billion | CN¥1.04 Billion | CN¥- | CN¥735.04 Million | ▲ +3.2 pp |
| 2012 | 137.8% | CN¥1.05 Billion | CN¥1.05 Billion | CN¥- | CN¥760.05 Million | ▲ +29.9 pp |
| 2011 | 107.9% | CN¥931.73 Million | CN¥931.73 Million | CN¥- | CN¥863.60 Million | ▲ +8.7 pp |
| 2010 | 99.1% | CN¥832.14 Million | CN¥832.14 Million | CN¥- | CN¥839.35 Million | ▲ +8.8 pp |
| 2009 | 90.3% | CN¥737.74 Million | CN¥737.74 Million | CN¥- | CN¥816.91 Million | ▲ +19.7 pp |
| 2008 | 70.6% | CN¥572.79 Million | CN¥572.79 Million | CN¥- | CN¥811.28 Million | ▲ +9.0 pp |
| 2007 | 61.6% | CN¥414.39 Million | CN¥414.39 Million | CN¥- | CN¥673.00 Million | ▼ -12.7 pp |
| 2006 | 74.2% | CN¥354.64 Million | CN¥354.64 Million | CN¥- | CN¥477.68 Million | ▲ +4.5 pp |
| 2005 | 69.8% | CN¥370.97 Million | CN¥370.97 Million | CN¥- | CN¥531.76 Million | ▲ +2.4 pp |
| 2004 | 67.4% | CN¥352.54 Million | CN¥352.54 Million | CN¥- | CN¥523.19 Million | ▲ +4.1 pp |
| 2003 | 63.2% | CN¥325.43 Million | CN¥325.43 Million | CN¥- | CN¥514.56 Million | ▲ +8.5 pp |
| 2002 | 54.8% | CN¥277.54 Million | CN¥277.54 Million | CN¥- | CN¥506.86 Million | ▲ +2.1 pp |
| 2001 | 52.7% | CN¥256.61 Million | CN¥256.61 Million | CN¥- | CN¥486.87 Million | ▲ +7.3 pp |
| 2000 | 45.4% | CN¥218.78 Million | CN¥218.78 Million | CN¥- | CN¥481.54 Million | — |